Gain Therapeutics, Inc.
GANX
$1.58
-$0.07-4.24%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | 9.91M | 275.40K | 287.30K | 2.47M | 10.72M |
| Gross Profit | -9.91M | -275.40K | -287.30K | -2.47M | -10.72M |
| SG&A Expenses | 2.14M | 1.84M | 3.75M | 1.91M | 2.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.33M | 4.46M | 8.18M | 4.38M | 4.41M |
| Operating Income | -3.33M | -4.46M | -8.18M | -4.38M | -4.41M |
| Income Before Tax | -3.26M | -4.47M | -8.14M | -3.99M | -4.71M |
| Income Tax Expenses | 504.70K | 11.00K | 1.20K | 19.90K | 14.50K |
| Earnings from Continuing Operations | -3.77M | -4.49M | -8.14M | -4.01M | -4.72M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.77M | -4.49M | -8.14M | -4.01M | -4.72M |
| EBIT | -3.33M | -4.46M | -8.18M | -4.38M | -4.41M |
| EBITDA | -3.32M | -4.45M | -8.17M | -4.37M | -4.40M |
| EPS Basic | -0.14 | -0.17 | -0.42 | -0.22 | -0.31 |
| Normalized Basic EPS | -0.07 | -0.11 | -0.26 | -0.14 | -0.20 |
| EPS Diluted | -0.14 | -0.17 | -0.42 | -0.22 | -0.31 |
| Normalized Diluted EPS | -0.07 | -0.11 | -0.26 | -0.14 | -0.20 |
| Average Basic Shares Outstanding | 27.71M | 26.53M | 19.22M | 17.98M | 15.02M |
| Average Diluted Shares Outstanding | 27.71M | 26.53M | 19.22M | 17.98M | 15.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
